Edwards Lifesciences Appoints New CFO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy EW?
Edwards Lifesciences announced the appointment of Theodora Mistras as the company's corporate vice president and CFO, effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership roles in healthcare investment banking at Goldman Sachs. Mistras brings decades of healthcare leadership experience helping guide corporate boards and executive teams on corporate finance, strategy and investor relations. She holds a bachelor's degree in international studies from the University of Pennsylvania and a bachelor's degree in economics from the Wharton School.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 82.760
Low
84.00
Averages
96.52
High
105.00
Current: 82.760
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edwards Lifesciences Appoints New CFO
- Executive Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May, succeeding Scott Ullem, who will remain in an advisory role to ensure continuity in financial management.
- Background Overview: Prior to joining Edwards, Mistras served as CFO at Viatris since March 2024 and was a managing director in healthcare investment banking at Citigroup, bringing extensive financial and investment expertise to the role.
- Strategic Implications: Mistras's appointment aims to leverage her deep background in the healthcare sector and financial management skills to drive continued growth and innovation for Edwards in the cardiovascular medical device market.
- Transition Support: Scott Ullem's ongoing involvement will provide Mistras with essential support and guidance, ensuring that the company's strategic direction and financial stability remain unaffected during the executive transition.
See More
Edwards Lifesciences Appoints New Executive
- Executive Appointment: Edwards Lifesciences announced late Monday the appointment of Theodora Mistras as corporate vice president, a move aimed at strengthening the leadership team and enhancing strategic execution capabilities.
- Strategic Implications: Mistras's addition is expected to bring new perspectives and experience, particularly in innovation and market expansion within the medical device sector, further driving the company's business growth.
- Leadership Team Optimization: This appointment reflects the company's commitment to diversity and expertise within its executive team, aiming to enhance market competitiveness by introducing leaders with extensive industry experience.
- Future Outlook: As the healthcare industry rapidly evolves, Edwards Lifesciences aims to adapt to market changes through such executive transitions, ensuring it remains at the forefront of technological innovation and customer demand.
See More
Edwards Lifesciences Appoints New CFO
- New CFO Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May 2026, succeeding Scott Ullem, who has served in the role for over a decade, indicating a strategic transition in leadership.
- Extensive Financial Background: Mistras joins from Viatris, where she served as CFO since 2024, and has significant experience in healthcare finance from her roles at Citigroup Global Markets and Goldman Sachs, which will enhance the company's financial strategy.
- Sales Growth Forecast: Edwards Lifesciences anticipates a sales growth of 9%-11% for 2026, with adjusted earnings per share projected between $2.95 and $3.05, reflecting strong confidence in market demand and operational performance.
- TAVR Guidance Increase: The company has raised its transcatheter aortic valve replacement (TAVR) guidance to a range of 7%-9%, indicating increased product demand and potential for further revenue growth and market share expansion.
See More
EDWARDS LIFESCIENCES NAMES NEW CFO
- Announcement of Appointment: Edward S. Life Sciences has announced the appointment of a new Chief Financial Officer (CFO).
- Significance of the Appointment: The new CFO is expected to bring valuable expertise and leadership to the company's financial operations.
See More
Edwards Lifesciences Announces 10-Year COMMENCE Trial Results
- Long-Term Durability Evidence: The 10-year data from the COMMENCE trial shows that patients treated with surgical valves featuring RESILIA tissue have a 97.9% freedom from structural valve deterioration (SVD), indicating not only the long-term durability of this technology but also its potential to reduce the need for repeat procedures, thereby enhancing quality of life.
- Hope for Younger Patients: Despite enrolling younger patients who historically face higher risks of valve deterioration, the trial reported a 97.8% freedom from reoperation and a 98.6% freedom from non-structural valve dysfunction, underscoring the potential of RESILIA tissue to change treatment decision-making for physicians.
- Industry Leadership: With nearly 70 years of experience in structural heart innovation, Edwards Lifesciences reinforces its position as a standard-bearer in evaluating valve performance and durability through the COMMENCE trial, which supports its clinical evidence for surgical and transcatheter therapies.
- Ongoing Technological Advancements: Designed to enhance the durability of tissue valves, RESILIA tissue employs advanced calcium blocking processes and dry storage, and as patient lifespans increase, the continuous development of this technology will provide more reliable long-term treatment options for heart teams and patients.
See More
Edwards Lifesciences Announces 10-Year COMMENCE Trial Results
- Long-Term Durability Data: The 10-year results from the COMMENCE trial indicate that patients treated with surgical valves featuring RESILIA tissue have a 97.9% freedom from structural valve deterioration (SVD), suggesting the potential of this technology to change treatment approaches for younger patients.
- Reduced Reoperation Needs: The trial showed only a 2.2% reoperation rate due to SVD over 10 years, which not only lowers the risk of repeat surgeries for patients but also enhances their quality of life, particularly as life expectancy increases.
- Strengthened Clinical Evidence: Edwards Lifesciences' leadership in structural heart innovation is further solidified, as the data from the COMMENCE trial complements long-term outcomes from the PARTNER trial series, boosting confidence in its surgical and transcatheter therapies.
- Technological Innovation and Market Demand: The design of RESILIA tissue aims to resist calcification and extend valve longevity, and as patients increasingly expect long-term durability and active lifestyles, the demand for this technology is expected to continue growing.
See More
Edwards Lifesciences Appoints New CFO
- Executive Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May, succeeding Scott Ullem, who will remain in an advisory role to ensure continuity in financial management.
- Background Overview: Prior to joining Edwards, Mistras served as CFO at Viatris since March 2024 and was a managing director in healthcare investment banking at Citigroup, bringing extensive financial and investment expertise to the role.
- Strategic Implications: Mistras's appointment aims to leverage her deep background in the healthcare sector and financial management skills to drive continued growth and innovation for Edwards in the cardiovascular medical device market.
- Transition Support: Scott Ullem's ongoing involvement will provide Mistras with essential support and guidance, ensuring that the company's strategic direction and financial stability remain unaffected during the executive transition.
See More
Edwards Lifesciences Appoints New Executive
- Executive Appointment: Edwards Lifesciences announced late Monday the appointment of Theodora Mistras as corporate vice president, a move aimed at strengthening the leadership team and enhancing strategic execution capabilities.
- Strategic Implications: Mistras's addition is expected to bring new perspectives and experience, particularly in innovation and market expansion within the medical device sector, further driving the company's business growth.
- Leadership Team Optimization: This appointment reflects the company's commitment to diversity and expertise within its executive team, aiming to enhance market competitiveness by introducing leaders with extensive industry experience.
- Future Outlook: As the healthcare industry rapidly evolves, Edwards Lifesciences aims to adapt to market changes through such executive transitions, ensuring it remains at the forefront of technological innovation and customer demand.
See More
Edwards Lifesciences Appoints New CFO
- New CFO Appointment: Edwards Lifesciences has announced the appointment of Theodora Mistras as Chief Financial Officer effective at the end of May 2026, succeeding Scott Ullem, who has served in the role for over a decade, indicating a strategic transition in leadership.
- Extensive Financial Background: Mistras joins from Viatris, where she served as CFO since 2024, and has significant experience in healthcare finance from her roles at Citigroup Global Markets and Goldman Sachs, which will enhance the company's financial strategy.
- Sales Growth Forecast: Edwards Lifesciences anticipates a sales growth of 9%-11% for 2026, with adjusted earnings per share projected between $2.95 and $3.05, reflecting strong confidence in market demand and operational performance.
- TAVR Guidance Increase: The company has raised its transcatheter aortic valve replacement (TAVR) guidance to a range of 7%-9%, indicating increased product demand and potential for further revenue growth and market share expansion.
See More
EDWARDS LIFESCIENCES NAMES NEW CFO
- Announcement of Appointment: Edward S. Life Sciences has announced the appointment of a new Chief Financial Officer (CFO).
- Significance of the Appointment: The new CFO is expected to bring valuable expertise and leadership to the company's financial operations.
See More
Edwards Lifesciences Announces 10-Year COMMENCE Trial Results
- Long-Term Durability Evidence: The 10-year data from the COMMENCE trial shows that patients treated with surgical valves featuring RESILIA tissue have a 97.9% freedom from structural valve deterioration (SVD), indicating not only the long-term durability of this technology but also its potential to reduce the need for repeat procedures, thereby enhancing quality of life.
- Hope for Younger Patients: Despite enrolling younger patients who historically face higher risks of valve deterioration, the trial reported a 97.8% freedom from reoperation and a 98.6% freedom from non-structural valve dysfunction, underscoring the potential of RESILIA tissue to change treatment decision-making for physicians.
- Industry Leadership: With nearly 70 years of experience in structural heart innovation, Edwards Lifesciences reinforces its position as a standard-bearer in evaluating valve performance and durability through the COMMENCE trial, which supports its clinical evidence for surgical and transcatheter therapies.
- Ongoing Technological Advancements: Designed to enhance the durability of tissue valves, RESILIA tissue employs advanced calcium blocking processes and dry storage, and as patient lifespans increase, the continuous development of this technology will provide more reliable long-term treatment options for heart teams and patients.
See More
Edwards Lifesciences Announces 10-Year COMMENCE Trial Results
- Long-Term Durability Data: The 10-year results from the COMMENCE trial indicate that patients treated with surgical valves featuring RESILIA tissue have a 97.9% freedom from structural valve deterioration (SVD), suggesting the potential of this technology to change treatment approaches for younger patients.
- Reduced Reoperation Needs: The trial showed only a 2.2% reoperation rate due to SVD over 10 years, which not only lowers the risk of repeat surgeries for patients but also enhances their quality of life, particularly as life expectancy increases.
- Strengthened Clinical Evidence: Edwards Lifesciences' leadership in structural heart innovation is further solidified, as the data from the COMMENCE trial complements long-term outcomes from the PARTNER trial series, boosting confidence in its surgical and transcatheter therapies.
- Technological Innovation and Market Demand: The design of RESILIA tissue aims to resist calcification and extend valve longevity, and as patients increasingly expect long-term durability and active lifestyles, the demand for this technology is expected to continue growing.
See More
